Botulinum toxin therapy for chronic anal fissures

Where are we at currently?

Anthony Dat, Martin Chin, Stewart Skinner, Chip Farmer, Roger Wale, Peter Carne, Stephen Bell, Satish K Warrier

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)

Abstract

Background: Botulinum toxin (Botox) injection for chronic anal fissure (CAF) is commonly performed, yet there remains no consensus on optimal dosage or frequency of injections required to achieve complete resolution of anal fissure. The aim of this study was to determine the effectiveness of Botox and side-effect profile in the management of CAF. Methods: A retrospective clinical study of patients between 2010 and 2014 who underwent a Botox injection for CAF at a tertiary centre was performed. The effectiveness of Botox was measured using standardized outcomes including overall healing rate, presence of anal pain, recurrence and need for repeat botulinum injection. Binary outcomes were assessed using logistic regression model. The analysis was performed using Stata version 13 (StataCorp, College Station, TX, USA). Results: One hundred and one patients underwent 126 Botox injections within the study period. The mean first post-operative visit was at 1 month. The overall recurrence rate was 32%. The majority of patients were given 33U. No statistically significant relationship between dose and recurrence was identified. The presence of pain at the first post-operative visit was a predictor of future recurrence (odds ratio 3.92, confidence interval 1.58-9.74, P = 0.003). Conclusion: Botox is an effective strategy for CAF. Low doses can be given with good efficacy as highlighted by our audit and has the potential for great cost saving. The best predictor of recurrence is the presence of pain at the first post-procedure visit.

Original languageEnglish
Pages (from-to)E70-E73
Number of pages4
JournalANZ Journal of Surgery
Volume87
Issue number9
DOIs
Publication statusPublished - Sep 2017
Externally publishedYes

Keywords

  • Anal fissure
  • Botox
  • Botulinum toxin
  • Dose
  • Recurrence

Cite this

@article{a78dbcaec8084add8ab5ffb0a80ffda1,
title = "Botulinum toxin therapy for chronic anal fissures: Where are we at currently?",
abstract = "Background: Botulinum toxin (Botox) injection for chronic anal fissure (CAF) is commonly performed, yet there remains no consensus on optimal dosage or frequency of injections required to achieve complete resolution of anal fissure. The aim of this study was to determine the effectiveness of Botox and side-effect profile in the management of CAF. Methods: A retrospective clinical study of patients between 2010 and 2014 who underwent a Botox injection for CAF at a tertiary centre was performed. The effectiveness of Botox was measured using standardized outcomes including overall healing rate, presence of anal pain, recurrence and need for repeat botulinum injection. Binary outcomes were assessed using logistic regression model. The analysis was performed using Stata version 13 (StataCorp, College Station, TX, USA). Results: One hundred and one patients underwent 126 Botox injections within the study period. The mean first post-operative visit was at 1 month. The overall recurrence rate was 32{\%}. The majority of patients were given 33U. No statistically significant relationship between dose and recurrence was identified. The presence of pain at the first post-operative visit was a predictor of future recurrence (odds ratio 3.92, confidence interval 1.58-9.74, P = 0.003). Conclusion: Botox is an effective strategy for CAF. Low doses can be given with good efficacy as highlighted by our audit and has the potential for great cost saving. The best predictor of recurrence is the presence of pain at the first post-procedure visit.",
keywords = "Anal fissure, Botox, Botulinum toxin, Dose, Recurrence",
author = "Anthony Dat and Martin Chin and Stewart Skinner and Chip Farmer and Roger Wale and Peter Carne and Stephen Bell and Warrier, {Satish K}",
year = "2017",
month = "9",
doi = "10.1111/ans.13329",
language = "English",
volume = "87",
pages = "E70--E73",
journal = "ANZ Journal of Surgery",
issn = "1445-1433",
publisher = "Wiley-Blackwell",
number = "9",

}

Botulinum toxin therapy for chronic anal fissures : Where are we at currently? / Dat, Anthony; Chin, Martin; Skinner, Stewart; Farmer, Chip; Wale, Roger; Carne, Peter; Bell, Stephen; Warrier, Satish K.

In: ANZ Journal of Surgery, Vol. 87, No. 9, 09.2017, p. E70-E73.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Botulinum toxin therapy for chronic anal fissures

T2 - Where are we at currently?

AU - Dat, Anthony

AU - Chin, Martin

AU - Skinner, Stewart

AU - Farmer, Chip

AU - Wale, Roger

AU - Carne, Peter

AU - Bell, Stephen

AU - Warrier, Satish K

PY - 2017/9

Y1 - 2017/9

N2 - Background: Botulinum toxin (Botox) injection for chronic anal fissure (CAF) is commonly performed, yet there remains no consensus on optimal dosage or frequency of injections required to achieve complete resolution of anal fissure. The aim of this study was to determine the effectiveness of Botox and side-effect profile in the management of CAF. Methods: A retrospective clinical study of patients between 2010 and 2014 who underwent a Botox injection for CAF at a tertiary centre was performed. The effectiveness of Botox was measured using standardized outcomes including overall healing rate, presence of anal pain, recurrence and need for repeat botulinum injection. Binary outcomes were assessed using logistic regression model. The analysis was performed using Stata version 13 (StataCorp, College Station, TX, USA). Results: One hundred and one patients underwent 126 Botox injections within the study period. The mean first post-operative visit was at 1 month. The overall recurrence rate was 32%. The majority of patients were given 33U. No statistically significant relationship between dose and recurrence was identified. The presence of pain at the first post-operative visit was a predictor of future recurrence (odds ratio 3.92, confidence interval 1.58-9.74, P = 0.003). Conclusion: Botox is an effective strategy for CAF. Low doses can be given with good efficacy as highlighted by our audit and has the potential for great cost saving. The best predictor of recurrence is the presence of pain at the first post-procedure visit.

AB - Background: Botulinum toxin (Botox) injection for chronic anal fissure (CAF) is commonly performed, yet there remains no consensus on optimal dosage or frequency of injections required to achieve complete resolution of anal fissure. The aim of this study was to determine the effectiveness of Botox and side-effect profile in the management of CAF. Methods: A retrospective clinical study of patients between 2010 and 2014 who underwent a Botox injection for CAF at a tertiary centre was performed. The effectiveness of Botox was measured using standardized outcomes including overall healing rate, presence of anal pain, recurrence and need for repeat botulinum injection. Binary outcomes were assessed using logistic regression model. The analysis was performed using Stata version 13 (StataCorp, College Station, TX, USA). Results: One hundred and one patients underwent 126 Botox injections within the study period. The mean first post-operative visit was at 1 month. The overall recurrence rate was 32%. The majority of patients were given 33U. No statistically significant relationship between dose and recurrence was identified. The presence of pain at the first post-operative visit was a predictor of future recurrence (odds ratio 3.92, confidence interval 1.58-9.74, P = 0.003). Conclusion: Botox is an effective strategy for CAF. Low doses can be given with good efficacy as highlighted by our audit and has the potential for great cost saving. The best predictor of recurrence is the presence of pain at the first post-procedure visit.

KW - Anal fissure

KW - Botox

KW - Botulinum toxin

KW - Dose

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=84945980436&partnerID=8YFLogxK

U2 - 10.1111/ans.13329

DO - 10.1111/ans.13329

M3 - Article

VL - 87

SP - E70-E73

JO - ANZ Journal of Surgery

JF - ANZ Journal of Surgery

SN - 1445-1433

IS - 9

ER -